Home

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4

Repository of Nicolaus Copernicus University

Show simple item record

dc.contributor.author Domagalski, Krzysztof
dc.contributor.author Pawłowska, M.
dc.contributor.author Halota, W.
dc.contributor.author Smukalska, E.
dc.contributor.author Linkowska, K.
dc.contributor.author Grzybowski, T.
dc.contributor.author Tretyn, Andrzej
dc.date.accessioned 2017-04-27T12:16:46Z
dc.date.available 2017-04-27T12:16:46Z
dc.date.issued 2013-01-13
dc.identifier.citation European Journal of Clinical Microbiology and Infectious Diseases vol. 32, issue 6, 2013,pp.745–754
dc.identifier.issn 0934-9723
dc.identifier.issn ESSN: 1435-4373
dc.identifier.other DOI 10.1007/s10096-012-1799-z
dc.identifier.uri http://repozytorium.umk.pl/handle/item/4321
dc.description.abstract IL-28B polymorphisms are predictors of response to therapy in adults infected with hepatitis C. We do not know whether they are markers of response to therapy in children and adolescents. The aim of this study was to determine whether single-nucleotide polymorphisms (SNPs) in the IL-28B gene could influence the probability of response to therapy compared with other known baseline prognostic factors and correlate with clinical findings in pediatric patients infected with hepatitis C virus (HCV) genotypes 1 or 4. We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNα/RBV). Treatment response and clinical data were analyzed. Overall, sustained virological response (SVR) was achieved by 45 % of patients infected with difficult-to-treat HCV genotypes 1 and 4. Except for IL-28B polymorphisms, there was no association of SVR with any other clinical data. IL-28B rs12979860 CC [odds ratio (OR), 6.81; p = 0.001] and rs8099917 TT (OR, 3.14; p = 0.013) genotypes were associated with higher SVR rates. IL-28B rs12980275 was not significantly associated with SVR ( p = 0.058). Only the distribution between CC and CT-TT genotypes of rs12979860 significantly differentiated patients achieving early virological response (EVR) (OR, 10.0; p = 0.011). Children with the rs12979860 CC genotype had significantly higher baseline viral load compared with CT-TT patients ( p = 0.010). In children and adolescents chronically infected with HCV genotypes 1 and 4, IL-28B rs12979860 and rs8099917 polymorphisms were the only predictors of response to peg-IFN/RBV.
dc.description.sponsorship Financial support: This study was supported by the Ministry of Science and Higher Education (MNiSW, grant no. N402 584440) and Nicolaus Copernicus University (UMK, grant no. MN-4/WL-SD)
dc.language.iso eng
dc.publisher Springer
dc.rights Attribution-NoDerivs 3.0 Poland
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nd/3.0/pl/
dc.subject Interleukins
dc.subject Ribavrin
dc.subject Single nucleotide polymorphisms
dc.subject Interferons
dc.subject Hepatitis C virus
dc.subject Viral load
dc.title Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
dc.type info:eu-repo/semantics/article


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NoDerivs 3.0 Poland Except where otherwise noted, this item's license is described as Attribution-NoDerivs 3.0 Poland

Search repository



Advanced Search

Browse

My Account

Statistics

Informations